Afuco™ Anti-Human TNFSF14 ADCC Recombinant Antibody (SAR252067), ADCC Enhanced (CAT#: AFC-615CL)

Anti-TNFSF14 ADCC Enhanced Antibody (SAR252067) is an ADCC enhanced antibody produced by our Afuco™ platform. SAR 252067 is an anti-LIGHT fully human monoclonal antibody that is being developed for the treatment of ulcerative colitis and crohn's disease.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 Mean serum concentration of SAR252067 with each dose over time, shown in (A) Cartesian plot (mean ± SD) and (B) semi-log plot.

Figure 1 Mean serum concentration of SAR252067 with each dose over time, shown in (A) Cartesian plot (mean ± SD) and (B) semi-log plot.

Zhang, M., Perrin, L., & Pardo, P. (2017). A Randomized Phase 1 Study to Assess the Safety and Pharmacokinetics of the Subcutaneously Injected Anti‐LIGHT Antibody, SAR252067. Clinical pharmacology in drug development, 6(3), 292-301.

Figure 2 SAR252067 serum levels over the entire dose range, illustrated by (A) Cmax and (B) AUC0-∞.

Figure 2 SAR252067 serum levels over the entire dose range, illustrated by (A) Cmax and (B) AUC0-∞.

Zhang, M., Perrin, L., & Pardo, P. (2017). A Randomized Phase 1 Study to Assess the Safety and Pharmacokinetics of the Subcutaneously Injected Anti‐LIGHT Antibody, SAR252067. Clinical pharmacology in drug development, 6(3), 292-301.

FuncS

Figure 3 Summary plots of individual sLIGHT values (mean ± SE) over time.

Figure 3 Summary plots of individual sLIGHT values (mean ± SE) over time.

Zhang, M., Perrin, L., & Pardo, P. (2017). A Randomized Phase 1 Study to Assess the Safety and Pharmacokinetics of the Subcutaneously Injected Anti‐LIGHT Antibody, SAR252067. Clinical pharmacology in drug development, 6(3), 292-301.


Specifications

  • Host Species
  • Human
  • Derivation
  • Human
  • Type
  • ADCC enhanced antibody
  • Species Reactivity
  • Human
  • Applications
  • FuncS
  • Related Disease
  • Autoimmune Diseases; Crohn's Disease; Ulcerative Colitis

Product Property

  • Purity
  • >90% assessed by SDS-PAGE
  • Storage
  • ≤6 months at 4°C; ≥6 months at -20°C.

Applications

  • Application Notes
  • The antibody was validated for Function Assay. For details, refer to Published Data.

Target

  • Alternative Names
  • TNFSF14; tumor necrosis factor (ligand) superfamily, member 14; LTg; TR2; CD258; HVEML; LIGHT; tumor necrosis factor ligand superfamily member 14; delta transmembrane LIGHT; herpesvirus entry mediator A; herpesvirus entry mediator ligand; herpesvirus entry mediator-ligand; herpes virus entry mediator ligand; ligand for herpesvirus entry mediator; tumor necrosis factor receptor-like 2; tumor necrosis factor superfamily member LIGHT

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "TNFSF14"

Human Antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for AFC-615CL. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare